Journal List > J Korean Thyroid Assoc > v.6(1) > 1056527

Ka, Jae, In-Ju, Hee-Seung, Jaetae, Woong, Jae, and Young: The Diagnosis and Management of Hyperthyroidism Consensus - Report of the Korean Thyroid Association

References

1. Cho BY. Clinical thyroidology. 3rd ed. Seoul, Korea: Korea Medical Book Publisher;2010.
2. Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol. 2010; 322(1-2):125–34.
crossref
3. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21(6):593–646.
crossref
4. Cho BY, Koh CS. Current trends in the diagnosis and treatment of Graves’ disease in Korea. Endocrinol Metab. 1992; 7(3):216–27.
5. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991; 1(2):129–35.
crossref
6. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab. 2010; 95(6):2715–26.
crossref
7. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007; 116(15):1725–35.
crossref
8. European Heart Rhythm A, Heart Rhythm S, Fuster V, Ryden LE, Cannom DS, Crijns HJ, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationexecutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48(4):854–906.
9. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003; 148(4):433–42.
crossref
10. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med. 1995; 123(8):572–83.
crossref
11. Shigemasa C, Abe K, Taniguchi S, Mitani Y, Ueda Y, Adachi T, et al. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves’ disease despite similar serum total T4 levels. J Clin Endocrinol Metab. 1987; 65(2):359–63.
12. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf). 2001; 55(3):381–90.
crossref
13. Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab. 2008; 4(2):70–1.
crossref
14. Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS. Graves’ disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med. 1989; 87(5):558–61.
crossref
15. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med. 1994; 121(4):281–8.
crossref
16. Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, et al. Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005; 15(11):1279–86.
crossref
17. Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg. 2009; 144(5):399–406.
crossref
18. Cooper DS. Antithyroid drugs. N Engl J Med. 2005; 352(9):905–17.
crossref
19. Cooper DS. Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. Ann Intern Med. 1985; 102(3):328–31.
20. Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003; 88(8):3474–81.
crossref
21. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol. 2005; 153(4):489–98.
crossref
22. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007; 146(9):657–65.
crossref
23. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest. 1994; 17(1):29–36.
24. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother. 2003; 37(2):224–8.
crossref
25. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, et al. The Role of Propylthiouracil in the Management of Graves’ Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009; 19(7):673–4.
crossref
26. FDA, U.S.Food and Drug Administration information for healthcare professionals-propylthiouracil-induced liver failure. 2009; Available from:. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm162701.htm.
27. Vilchez FJ, Torres I, Garcia-Valero A, Lopez-Tinoco C, de Los Santos A, Aguilar-Diosdado M. Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. Ann Pharmacother. 2006; 40(11):2059–63.
crossref
28. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002; 8(3):222–4.
crossref
29. Park G, Kim HJ, Jang HC, Chung H. A case of aplasia cutis congenita after methimazole exposure during pregnancy. Korean J Dermatol. 2006; 44(5):642–4.
30. Kim MJ, Kim MJ, Cho GR, Chueh HW, Jung JA, Lee YS, et al. Aplasia cutis congenita in a baby born to hyperthyroid mother treated with methimazole during pregnancy: a case report. J Korean Soc Pediatr Endocrinol. 2008; 13(1):100–3.
31. Wolf D, Foulds N, Daya H. Antenatal carbimazole and choanal atresia: a new embryopathy. Arch Otolaryngol Head Neck Surg. 2006; 132(9):1009–11.
32. Clark SM, Saade GR, Snodgrass WR, Hankins GD. Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. Ther Drug Monit. 2006; 28(4):477–83.
crossref
33. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, et al. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest. 2008; 31(10):866–72.
crossref
34. The Japan Thyroid Association.Guideline for the treatment of Graves’ disease with antithyroid drug in Japan. Tokyo: Nankodo Co., Ltd;2006.
35. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Graves’ disease? J Endocrinol Invest. 2002; 25(2):152–7.
crossref
36. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2000; 85(3):1038–42.
crossref
37. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol. 2002; 147(5):583–9.
crossref
38. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C. Remission of Graves’ hyperthyroidism treated with methimazole. Rev Invest Clin. 2002; 54(4):307–10.
39. Orgiazzi J, Madec AM. Reduction of the risk of relapse after withdrawal of medical therapy for Graves’ disease. Thyroid. 2002; 12(10):849–53.
crossref
40. Glinoer D, de Nayer P, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol. 2001; 144(5):475–83.
crossref
41. Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A. Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid. 2000; 10(10):891–6.
crossref
42. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med. 1983; 75(2):353–9.
43. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007; 334(7592):514.
crossref
44. Delit C, Silver S, Yohalem SB, Segal RL. Thyrocardiac disease and its management with radioactive iodine I-131. JAMA. 1961; 176:262–7.
crossref
45. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves’ disease. J Clin Endocrinol Metab. 2001; 86(7):3016–21.
crossref
46. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1999; 84(11):4012–6.
crossref
47. Klein I. Endocrine disorders and cardiovascular disease. In:. Libby P, editor. editor.Braunwald's heart disease: a textbook of cardiovascular medicine. Philadelphia, PA: Saunders Elsevier;2008; 2033–47.
crossref
48. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid. 2004; 14(7):525–30.
crossref
49. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995; 25(3):186–93.
50. Fisher WD, Voorhess ML, Gardner LI. Congenital hypothyroidism in infant following maternal I-131 therapy with a review of hazards of environmental radioisotope contamination. J Pediatr. 1963; 62:132–46.
51. Berg GE, Nystrom EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, et al. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998; 39(2):357–61.
52. Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves’ disease. Am J Med. 1995; 99(2):173–9.
crossref
53. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002; 87(3):1073–7.
54. Erbil Y, Ozluk Y, Giris M, Salmaslioglu A, Issever H, Barbaros U, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007; 92(6):2182–9.
crossref
55. Ansaldo GL, Pretolesi F, Varaldo E, Meola C, Minuto M, Borgonovo G, et al. Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter. J Am Coll Surg. 2000; 191(6):607–12.
56. Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf). 1991; 35(5):439–42.
crossref
57. Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: A meta-analysis. J Surg Res. 2000; 90(2):161–5.
crossref
58. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998; 228(3):320–30.
crossref
59. Sosa JA, Mehta PJ, Wang TS, Boudourakis L, Roman SA. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? J Am Coll Surg. 2008; 206(3):1097–105.
crossref
60. Jumaily JS, Noordzij JP, Dukas AG, Lee SL, Bernet VJ, Payne RJ, et al. Prediction of hypocalcemia after using 1- to 6-hour postoperative parathyroid hormone and calcium levels: an analysis of pooled individual patient data from 3 observational studies. Head Neck. 2010; 32(4):427–34.
crossref
61. McLeod IK, Arciero C, Noordzij JP, Stojadinovic A, Peoples G, Melder PC, et al. The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. Thyroid. 2006; 16(3):259–65.
crossref
62. Kaplan EL, Angelos P. Thyroid disease manager, Chapter 21, Surgery of the thyroid gland. May 18,. 2010; Available from:. www.thyroidmanager.org/Chapter21/21-frame.htm.
63. Noordzij JP, Lee SL, Bernet VJ, Payne RJ, Cohen SM, McLeod IK, et al. Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies. J Am Coll Surg. 2007; 205(6):748–54.
crossref
64. Cote V, Sands N, Hier MP, Black MJ, Tamilia M, MacNamara E, et al. Cost savings associated with post-thyroidectomy parathyroid hormone levels. Otolaryngol Head Neck Surg. 2008; 138(2):204–8.
crossref
65. Bellantone R, Lombardi CP, Raffaelli M, Boscherini M, Alesina PF, De Crea C. et al. Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? Surgery. 2002; 132(6):1109–12. discussion 12-3.
66. Wilson RB, Erskine C, Crowe PJ. Hypomagnesemia and hypocalcemia after thyroidectomy: prospective study. World J Surg. 2000; 24(6):722–6.
crossref
67. Roh JL, Park CI. Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. Am J Surg. 2006; 192(5):675–8.
crossref
TOOLS
Similar articles